Mesenkia Therapeutics AB
PrivateLast Round
VC Round
May 22, 2026
Total Funding Raised
$590,000
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Mesenkia Therapeutics AB operates in Healthcare & Life Sciences and is based in Uppsala. Its latest recorded funding round was a VC Round in May 2026.
Mesenkia Therapeutics AB is a biotechnology company that develops biological drug candidates for the treatment of glioblastoma.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mesenkia Therapeutics AB Comparables
Compare Mesenkia Therapeutics AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adaptin Bio | 81% | |
| Targepeutics | 79% | |
| Nascent Biotech, Inc. | 74% |
For institutional investors. Book with your work email.
Mesenkia Therapeutics AB Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | May 22, 2026 | ||||
| Seed | Jun 2, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Mesenkia Therapeutics AB Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Almi Invest AB | Seed |
| Uppsala University Invest | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 24, 2026
Grew 60% from 5 to 8 employees this quarter.
- May 22, 2026
Raised a VC Round with participation from lsi-zeta.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 19, 2026
Mesenkia Therapeutcs AB and BioArctic explore a novel antibody-based approach for glioblastoma under a research collaboration agreement in Sweden on Aug 19th '26, combining BioArctic's BrainTransporter technology with Mesenkia Therapeutcs AB's antibody platform and planning preclinical studies.
For institutional investors. Book with your work email.
Mesenkia Therapeutics AB Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mesenkia Therapeutics AB's valuation, stock price, and market status.
Is Mesenkia Therapeutics AB a public or private company?
Mesenkia Therapeutics AB is a private company.
What is the current stock price of Mesenkia Therapeutics AB?
Mesenkia Therapeutics AB is a private company, so its shares have no public market price. Caplight tracks Mesenkia Therapeutics AB's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mesenkia Therapeutics AB worth (valuation)?
Valuation information for Mesenkia Therapeutics AB is not publicly available.
Can I buy Mesenkia Therapeutics AB stock?
Mesenkia Therapeutics AB shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mesenkia Therapeutics AB's last funding round?
Mesenkia Therapeutics AB's most recent funding round was VC Round on May 22, 2026.
Who are the main investors in Mesenkia Therapeutics AB?
Key investors in Mesenkia Therapeutics AB include Almi Invest AB, Uppsala University Invest.
Will Mesenkia Therapeutics AB IPO soon?
No public IPO plans have been announced for Mesenkia Therapeutics AB.
How can I track Mesenkia Therapeutics AB secondary market activity?
Caplight tracks bids, offers, and trades in Mesenkia Therapeutics AB's shares on secondary markets.